Table 2.
Parameter | CSII | MDI | Difference at end point (95% CI) |
---|---|---|---|
A1C (%) | |||
Baseline | 7.7 ± 0.7 | 7.8 ± 0.6 | |
End point | 7.0 ± 0.8 | 7.2 ± 0.7 | −0.1 (−0.5 to 0.3) |
SMBG [mmol/l (mg/dl)] | |||
Fasting | |||
Baseline | 10.1 ± 3.3 (183 ± 60) | 10.4 ± 3.2 (188 ± 57) | |
End point | 6.8 ± 1.7 (123 ± 30) | 7.7 ± 2.4 (139 ± 43) | −0.7 (−1.8 to 0.5) |
Preprandial | |||
Baseline | 7.8 ± 3.6 (140 ± 64) | 8.0 ± 3.0 (145 ± 53) | |
End point | 6.7 ± 2.4 (120 ± 43) | 7.7 ± 2.4 (138 ± 42) | −0.9 (−2.3 to 0.4) |
Postprandial | |||
Baseline | 8.4 ± 3.6 (151 ± 66) | 6.9 ± 2.6 (125 ± 47) | |
End point | 8.2 ± 2.3 (147 ± 42) | 7.6 ± 2.1 (136 ± 39) | 0.3 (−1.1 to 1.7) |
0300 h blood glucose [mmol/l (mg/dl)] | |||
Baseline | 8.4 ± 4.8 (151 ± 87) | 7.8 ± 5.0 (141 ± 90) | |
End point | 8.8 ± 2.3 (158 ± 42) | 8.1 ± 4.3 (146 ± 78) | 3.0 (−0.4 to 6.5) |
Blood glucose [mmol/l (mg/dl)] | |||
Baseline | 9.1 ± 2.3 (164 ± 41) | 8.9 ± 1.6 (160 ± 30) | |
End point | 8.1 ± 1.8 (146 ± 32) | 8.0 ± 1.1 (144 ± 20) | 0.03 (−0.7 to 0.8) |
MAGE [mmol/l (mg/dl)] | |||
Baseline | 8.0 ± 2.4 (144 ± 43) | 7.6 ± 1.7 (137 ± 31) | |
End point | 6.4 ± 2.2 (115 ± 40) | 6.4 ± 2.1 (115 ± 38) | −0.4 (−1.8 to 1.0) |
Data are means ± SD unless otherwise indicated. The per-protocol population consisted of patients who were correctly randomized and receiving study insulin. MAGE, mean amplitude of glycemic excursion; SMBG, self-monitored blood glucose.